{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T23:16:48Z","timestamp":1788650208464,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T00:00:00Z","timestamp":1642291200000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.prdoa.2022.100133","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T18:46:25Z","timestamp":1642617985000},"page":"100133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson\u2019s disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"6","author":[{"given":"Simran","family":"Dahiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Tisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Greenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prdoa.2022.100133_b0005","unstructured":"K.L. Chou, Clinical manifestations of Parkinson disease. <https:\/\/www.uptodate.com\/contents\/clinical-manifestations-of-parkinson-disease?search=parkinsons%20disease%20adult&source=search_result&selectedTitle=1\u223c150&usage_type=default&display_rank=1#H8> (accessed 01.09.2020)."},{"key":"10.1016\/j.prdoa.2022.100133_b0010","unstructured":"J. Jankovic, Etiology and pathogenesis of Parkinson Disease. <https:\/\/www.uptodate.com\/contents\/etiology-and-pathogenesis-of-parkinson-disease?search=parkinsons%20disease%20adult&source=search_result&selectedTitle=5\u223c150&usage_type=default&display_rank=5> (accessed 01.09.2020)."},{"key":"10.1016\/j.prdoa.2022.100133_b0015","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/npp.2011.212","article-title":"Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa","volume":"37","author":"Smith","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.prdoa.2022.100133_b0020","unstructured":"H. Kelly, eTG complete > Type 2 diabetes in adults. <https:\/\/tgldcdp-tg-org-au.wwwproxy1.library.unsw.edu.au\/viewTopic?topicfile=type-2-diabetes-in-adults&sectionId=dbg1-c09-s4#tdbg1-c09-tbl2> (accessed 01.09.2020)."},{"key":"10.1016\/j.prdoa.2022.100133_b0025","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/00207454.2018.1543671","article-title":"The investigation of protective effects of glucagon-like peptide-1 (GLP-1) analogue exenatide against glucose and fructose-induced neurotoxicity","volume":"129","author":"Khalilnezhan","year":"2019","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.prdoa.2022.100133_b0030","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003549","article-title":"Risk of Parkinson Disease in Diabetes Mellitus: An Updated Meta-Analysis of Population-Based Cohort Studies","volume":"95","author":"Yue","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.prdoa.2022.100133_b0035","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.2337\/dc11-1584","article-title":"Diabetes and risk of Parkinson's disease: a systematic review and meta-analysis","volume":"34","author":"Cereda","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.prdoa.2022.100133_b0040","unstructured":"A. Rohatgi, WebPlotDigitzer. <https:\/\/automeris.io\/WebPlotDigitizer\/citation.html> (accessed 01.09.2020)."},{"key":"10.1016\/j.prdoa.2022.100133_b0045","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE's risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.prdoa.2022.100133_b0050","unstructured":"[Computer Program]. Review Manager (RevMan) Version 5.4. The Cochrane Collaboration, 2020."},{"issue":"1","key":"10.1016\/j.prdoa.2022.100133_b0055","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JPD-181503","article-title":"Semaglutide is Neuroprotective and Reduces \u03b1-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease","volume":"9","author":"Zhang","year":"2019","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"10.1016\/j.prdoa.2022.100133_b0060","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s12640-019-9998-3","article-title":"Sitagliptin and Liraglutide Modulate L-dopa Effect and Attenuate Dyskinetic Movements in Rotenone-Lesioned Rats","volume":"35","author":"Badawi","year":"2019","journal-title":"Neurotox Res"},{"key":"10.1016\/j.prdoa.2022.100133_b0065","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.npep.2018.07.003","article-title":"Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model","volume":"71","author":"Zhang","year":"2018","journal-title":"Neuropeptides"},{"issue":"3","key":"10.1016\/j.prdoa.2022.100133_b0070","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.amjms.2017.05.002","article-title":"Neuroprotective Effects of Eexenatide in a Rotenone-Induced Rat Model of Parkinson's Disease","volume":"354","author":"Aksoy","year":"2017","journal-title":"Am J Med Sci"},{"issue":"3","key":"10.1016\/j.prdoa.2022.100133_b0075","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10787-017-0331-6","article-title":"Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease","volume":"25","author":"Badawi","year":"2017","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.prdoa.2022.100133_b0080","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.brainres.2016.05.038","article-title":"Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease","volume":"1646","author":"Hansen","year":"2016","journal-title":"Brain Res"},{"key":"10.1016\/j.prdoa.2022.100133_b0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-2094-5-19","article-title":"Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease","volume":"5","author":"Harkavyi","year":"2008","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.prdoa.2022.100133_b0090","article-title":"The GLP-1\/GIP dual receptor agonist DA5-CH is superior to Exendin-4 in protecting neurons in the 6-OHDA rat Parkinson Model","author":"Zhang","year":"2020","journal-title":"ResearchGate"},{"key":"10.1016\/j.prdoa.2022.100133_b0095","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.neuropharm.2018.02.012","article-title":"Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease","volume":"133","author":"Feng","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.prdoa.2022.100133_b0100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2017.06.029","article-title":"A novel GLP-1\/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease","volume":"812","author":"Yuan","year":"2017","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.prdoa.2022.100133_b0105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.prdoa.2022.100133_b0110","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/ilar\/ilu042","article-title":"Meta-analyses of animal studies: an introduction of a valuable instrument to further improve healthcare","volume":"55","author":"Hooijmans","year":"2014","journal-title":"Ilar j"},{"key":"10.1016\/j.prdoa.2022.100133_b0115","doi-asserted-by":"crossref","unstructured":"J.A.C. Sterne, A.J. Sutton, J.P.A. Ionnaidis, N. Terrin, D.R. Jones, J. Lau, J. Carpenter, G. Rucker, R.M. Harbord, C.H. Schmid, J. Tetzlaff, J.J. Deeks, J. Peters, P. Macaskill, G. Schwarzer, S. Duval, D.G. Altman, D. Moher, J.P.T. Higgins, Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials, BMJ 343 (2011) d4002.","DOI":"10.1136\/bmj.d4002"},{"key":"10.1016\/j.prdoa.2022.100133_b0120","article-title":"Limitations of animal models of Parkinson's disease","volume":"2011","author":"Potashkin","year":"2010","journal-title":"Parkinsons Dis"},{"key":"10.1016\/j.prdoa.2022.100133_b0125","series-title":"Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects","first-page":"83","article-title":"Animal Models of Parkinson\u2019s Disease","author":"Konnova","year":"2018"},{"issue":"6","key":"10.1016\/j.prdoa.2022.100133_b0130","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson's disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.prdoa.2022.100133_b0135","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J Parkinsons Dis"},{"key":"10.1016\/j.prdoa.2022.100133_b0140","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/j.prdoa.2022.100133_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2019.104583","article-title":"Mechanism of the neuroprotective effect of GLP-1 in a rat model of Parkinson's with pre-existing diabetes","volume":"131","author":"Elbassuoni","year":"2019","journal-title":"Neurochem Int"},{"issue":"7","key":"10.1016\/j.prdoa.2022.100133_b0150","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"}],"updated-by":[{"DOI":"10.1016\/j.prdoa.2023.100193","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000}}],"container-title":["Clinical Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112522000044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590112522000044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:46:54Z","timestamp":1762912014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590112522000044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":30,"alternative-id":["S2590112522000044"],"URL":"https:\/\/doi.org\/10.1016\/j.prdoa.2022.100133","relation":{},"ISSN":["2590-1125"],"issn-type":[{"value":"2590-1125","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of GLP-1 receptor agonists in pre-clinical rodent models of Parkinson\u2019s disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prdoa.2022.100133","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100133"}}